EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Structural Cumulative Survival Models for Estimation of Treatment Effects Accounting for Treatment Switching in Randomized Experiments

Andrew Ying iD, Eric J Tchetgen Tchetgen

Biometrics · 01.09.2023 · 79 (3) · 1597-1609

DOI: 10.1111/biom.13704 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Biometrics, online erschienen am 05.06.2022. Verfasst von Andrew Ying und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Statistics and Data Science, The Wharton School, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Treatment Switching, HIV Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment switching in a randomized controlled trial occurs when a patient in one treatment arm switches to another arm during follow-up. This can occur at the point of disease progression, whereby patients in the control arm may be offered the experimental treatment. It is widely known that failure to account for treatment switching can seriously bias the estimated treatment causal effect. In this paper, we aim to account for the potential impact of treatment switching in a reanalysis evaluating the treatment effect of nucleoside reverse transcriptase inhibitors (NRTIs) on a safety outcome (time to first severe or worse sign or symptom) in participants receiving a new antiretroviral regimen that either included or omitted NRTIs in the optimized treatment that includes or omits NRTIs trial. We propose an estimator of a treatment causal effect for a censored time to event outcome under a structural cumulative survival model that leverages randomization as an instrumental variable to account for selective treatment switching. We establish that the proposed estimator is uniformly consistent and asymptotically Gaussian, with a consistent variance estimator and confidence intervals given, whose finite-sample performance is evaluated via extensive simulations. An R package ‘ivsacim’ implementing all proposed methods is freely available on R CRAN. Results indicate that adding NRTIs versus omitting NRTIs to a new optimized treatment regime may increase the risk for a safety outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Treatment SwitchingHIV InfectionsHumansTreatment Outcome

Stichwörter der Autor:innen

G-estimationinstrumental variabletreatment crossovertreatment switching

Autor:innen und Institutionen

  • Department of Statistics and Data Science, The Wharton School, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Andrew Ying

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Ying, A., & Tchetgen, E. J. T. (2023). Structural Cumulative Survival Models for Estimation of Treatment Effects Accounting for Treatment Switching in Randomized Experiments. Biometrics, 79(3), 1597-1609. https://doi.org/10.1111/biom.13704

Vancouver

Ying A, Tchetgen EJT. Structural Cumulative Survival Models for Estimation of Treatment Effects Accounting for Treatment Switching in Randomized Experiments. Biometrics. 2023;79(3):1597-1609. doi:10.1111/biom.13704

BibTeX
@article{Ying2023,
  author = {Ying, Andrew and Tchetgen, Eric J Tchetgen},
  title = {Structural Cumulative Survival Models for Estimation of Treatment Effects Accounting for Treatment Switching in Randomized Experiments},
  journal = {Biometrics},
  year = {2023},
  volume = {79},
  number = {3},
  pages = {1597--1609},
  doi = {10.1111/biom.13704}
}
Kostenlos starten →